# Dietary Flavonoids and Colorectal Adenoma Recurrence in the Polyp Prevention Trial

**Gerd Bobe**[1,2], **Leah B. Sansbury**[3], **Paul S. Albert**[4], **Amanda J. Cross**[5], **Lisa Kahle**[6], **Jason Ashby**[6], **Martha L. Slattery**[7], **Bette Caan**[8], **Electra Paskett**[9], **Frank Iber**[10], **James Walter Kikendall**[11], **Peter Lance**[12], **Cassandra Daston**[13], **James R. Marshall**[14], **Arthur Schatzkin**[5], and **Elaine Lanza**[1]

[1]*Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, Bethesda/ Frederick, Maryland* [2]*Cancer Prevention Fellowship Program, Office of Preventive, National Cancer Institute, Bethesda/Frederick, Maryland* [3]*Epidemiology and Genetics Research Program, Division of Cancer Control and Populations Science, National Cancer Institute, Bethesda/Frederick, Maryland* [4]*Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda/ Frederick, Maryland* [5]*Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda/Frederick, Maryland* [6]*Information Management Services, Inc., Rockville, Maryland* [7]*University of Utah, Salt Lake City, Utah* [8]*Kaiser Foundation Research Institute, Oakland, California* [9]*Ohio State Cancer Center, Columbus, Ohio* [10]*Edward Hines, Jr., Hospital, Veterans Affairs Medical Center, Hines, Illinois* [11]*Walter Reed Army Medical Center, Washington, District of Columbia* [12]*Arizona Cancer Center, University of Arizona, Tucson, Arizona* [13]*Daston Communications, Chapel Hill, North Carolina* [14]*Roswell Park Cancer Institute, Buffalo, New York*

## Abstract

Two recent case-control studies suggested that some flavonoid subgroups may play a role in preventing colorectal cancer. Previous prospective cohort studies generally reported no association; however, only a small subset of flavonoids was evaluated and partial flavonoid databases were used. We used the newly constructed U.S. Department of Agriculture flavonoid database to examine the association between consumption of total flavonoids, 6 flavonoid subgroups, and 29 individual flavonoids with adenomatous polyp recurrence in the Polyp Prevention Trial. The Polyp Prevention Trial was a randomized dietary intervention trial, which examined the effectiveness of a low-fat, high-fiber, high-fruit, and high-vegetable diet on adenoma recurrence. Intakes of flavonoids were estimated from a food frequency questionnaire. Multivariate logistic regression models (adjusted for age, body mass index, sex, regular non–steroidal anti-inflammatory use, and dietary fiber intake) were used to estimate odds ratios and 95% confidence intervals for both any and advanced adenoma recurrence within quartiles of energy-adjusted flavonoid intake (baseline, during the trial, and change during the trial). Total flavonoid intake was not associated with any or advanced adenoma recurrence. However, high intake of flavonols, which are at greater concentrations in beans, onions, apples, and tea, was associated with decreased risk of advanced adenoma recurrence (4th versus 1st quartile during the trial; odds ratio, 0.24; 95% confidence interval, 0.11, 0.53; $P_{trend} = 0.0006$). Similar inverse associations were observed to a smaller extent for isoflavonoids, the flavonol kaempferol, and the isoflavonoids genistein and formononetin. Our data suggest that a flavonol-rich diet may decrease the risk of advanced adenoma recurrence.

---

**Disclosure of Potential Conflicts of Interest** No potential conflicts of interest were disclosed.

## Introduction

Flavonoids are a group of bioactive polyphenols that constitute a sizable part (189 mg/d per person) of the U.S. diet (1). Flavonoids are distributed widely in the plant kingdom and are especially abundant in fruits, vegetables, seeds, spices, herbs, tea, cocoa, and wine (2). The six major subclasses of flavonoids are anthocyanidins (e.g., cyanidin, delphinidin; primary sources: red berries, red cabbages, cherries, grapes, and onions), flavan-3-ols (e.g., catechin, epicatechin; primary sources: tea, apples, and red wine), flavanones (e.g., hesperitin, naringenin; primary sources: oranges, lemons, and grapefruits), flavones (e.g., apigenin, luteolin; primary sources: celery, parsley, and thyme), flavonols (e.g., kaempferol, myricetin, quercetin; primary sources: apples, beans, broccoli, and onions), and isoflavonoids (e.g., daidzein, genistein; primary sources: beans and soy products).

Dietary change, both feasible and safe, represents a viable strategy for preventing colorectal cancer (CRC). Flavonoids inhibit the growth of human colon cancer cell lines (3–7) and restrict colorectal carcinogenesis in animal studies (8–10). Possible biological mechanisms involved in the anticarcinogenic properties of flavonoids include their antioxidative and anti-inflammatory properties. In addition, flavonoids induce differentiation and apoptosis, and inhibit metabolic carcinogen activation, cell proliferation, tumor cell adhesion and invasion, and angiogenesis (4–6). Prospective cohort studies generally observed no association between flavonoid consumption and CRC (11–16); however, only a small subset of flavonoids was evaluated, the intake ranges were limited (11–16), and the databases only contained a partial list of flavonoids from the major foods (17–21). Two recent case-control studies, both based on larger, updated, and tested flavonoid databases (22–24), suggested an inverse association between high flavonoid consumption, in particular flavonols, and CRC risk in humans (25, 26).

The objective of this study was to evaluate the association between consumption of total flavonoids, the 6 major flavonoid subgroups, and 29 individual flavonoids with risk of any or advanced adenoma recurrence in the Polyp Prevention Trial (PPT). We used the recently released 2006 U.S. Department of Agriculture (USDA) flavonoid database (27) and the 2002 USDA isoflavonoid database for foods (23).

## Materials and Methods

### Study Design and Population

The PPT was a 4-year randomized, multicenter, nutritional intervention trial to evaluate whether changing nutrition patterns toward a high-fiber (goal, ≥4.30 g/MJ or 18 g/1,000 kcal), high-fruit and high-vegetable (goal, ≥0.84 servings/MJ or 5 servings/d), and low-fat (goal, ≤20% of energy) diet is effective in inhibiting colorectal adenoma recurrence. Details of the study and effectiveness have been described previously (28–30). To be eligible for the PPT, participants had to be at least 35 years of age and have had at least one histologic confirmed colorectal adenoma identified by complete colonoscopy in the 6 months before study entry. Furthermore, participants had to be within 150% of their recommended weight, without a history of inflammatory bowel disease, bowel resection, adenomatous polyposis syndrome, or prior history of adenomas or CRC, and not currently using lipid-lowering medications. Between 1991 and 1994, recruited participants ($N = 2,079$) from eight clinical centers (listed in Appendix 1) were randomly assigned to either the control ($n = 1,042$) or the intervention ($n = 1,037$) group. Of the 2,079 participants, 1,905 (control, $n = 947$; intervention, $n = 958$) completed the study and were used for this analysis. The other 174 participants were not included because they died before the colonoscopy at year 4 ($n = 88$), did not have a colonoscopy at year 4 ($n = 72$), refused to participate ($n = 9$), had no adenoma at baseline ($n = 4$), or were seriously ill ($n = 1$; ref. 29). The institutional review boards of the National Cancer

Institute and each participating center approved the study, and all participants provided written, informed consent.

## Lifestyle and Dietary Data

At baseline ($T_0$) and at each of the four annual follow-up visits ($T_1$, $T_2$, $T_3$, $T_4$), participants were asked to bring all current medications, including dietary supplements. Participants completed an interviewer-administered questionnaire about demographic, clinical, medication and supplement use (including name, dosage, and frequency of use), and dietary information. They also provided a fasting blood sample for analysis of total cholesterol, carotenoids, and other biomarkers. At baseline, participants viewed instructional videos on how to estimate food portion size and how to complete the dietary assessment instruments. Dietary intake was determined using a modified Block-National Cancer Institute Food Frequency Questionnaire (FFQ; ref. 31), 4-day food records, and 24-h dietary recalls. Participants completed a 4-day food record and an FFQ at baseline and at each of the four annual follow-up visits. Trained nutritionists reviewed all FFQs and 4-day food records with participants. On average, participants in the intervention group decreased their fat intake by 30%, increased their fiber intake by 75%, and increased their fruit and vegetable intake, 0.36 to 0.48 servings/MJ (32). Because the PPT intervention was based on behavior modification within the intervention group, there was a range in adherence to the intervention goals with the top 20% of the intervention group far exceeding the actual PPT intervention goals, whereas others made none or little change in their diets (33). Participants in the intervention group decreased their body weight and cholesterol level and increased their serum carotenoid levels over the 4-year intervention period, which was consistent with changes in nutrient intake as assessed by the FFQ (32).

This study was based on data from the FFQ exclusively, which asked about the frequency of intake during the past year of 119 food and beverage items and about the average serving sizes. Compared with the 4-day food record and the 24-h recall, the FFQ slightly overestimated fat and underestimated fiber, fruit, and vegetable intake; and had acceptable correlations of macronutrients and micronutrients (0.46–0.68) when ranking the nutrients (31–34).

## Flavonoid Data

The FFQ contained 11 questions on fruit consumption, 21 questions on vegetable consumption (including soups), 12 questions on beverage consumption (including beer, fruit juices, tea, and wine), and 1 question on chocolate consumption. Intakes of most flavonoids were estimated from the 2006 USDA flavonoid database for 394 food items (27); isoflavonoid intakes were estimated from the 2002 USDA-Iowa State University isoflavonoid database for foods (23). Validity and reliability coefficients for the dietary flavonoids in the present study were not calculated. Total flavonoid intake was calculated from the sum of the six flavonoid subgroups: (*a*) anthocyanidins (sum of cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin); (*b*) flavan-3-ols [sum of (−)-epicatechin, (−)-epicatechin 3-gallate, (−)-epigallocatechin, (−)-epigallocatechin 3-gallate, (+)-catechin, (+)-gallocatechin, theaflavin, theaflavin-3,3′-digallate, theaflavin-3′-gallate, theaflavin-3-gallate, and thearubigins]; (*c*) flavanones (sum of hesperitin andnaringenin); (*d*) flavones (sum of apigenin and luteolin); (*e*) flavonols (sum of isorhamnetin, kaempferol, myricetin, and quercetin); and (*f*) isoflavonoids (sum of daidzein, genistein, formononetin, and biochanin A).

## Adenoma Assessment

Participants had a full colonoscopy at baseline ($T_0$), at the end of year 1 ($T_1$), and at the end of year 4 ($T_4$). The colonoscopy at the end of year 1 was used for detection and removal of any adenomas missed at baseline. If participants missed the year 1 colonoscopy (8.2%), a full colonoscopy was done at the end of year 2. Only pathologically confirmed adenomas diagnosed

at the end of year 4 were considered recurrent adenomas. In addition to descriptive data on all adenomas, two independent pathologists determined histologic features and degree of atypia. Recurrence of any adenoma was observed in 724 participants (control, $n = 374$; intervention, $n = 380$). Advanced adenoma recurrence, defined as $\geq 1$ cm in size, at least 25% villous component, or exhibiting high-grade dysplasia, was observed in 126 participants (control, $n = 66$; intervention, $n = 60$).

## Statistical Analyses

Statistical analyses were done using Statistical Analysis Systems, version 8.2 (SAS, Inc.) software. Intakes of flavonoids (in mg) and flavonoid-rich foods (in g) at $T_0$, $T_1$, $T_2$, and $T_3$ were energy adjusted by dividing by total caloric intake at $T_0$, $T_1$, $T_2$, and $T_3$, respectively (nutrient density method). Following this, we calculated baseline intake ($T_0$), intake during the trial [average ($T_1,T_2,T_3$)], intake change [average ($T_1,T_2,T_3$) – $T_0$], and overall intake [average ($T_0,T_1,T_2,T_3$)]. Using other energy-adjusting methods (e.g., residual method and standard multivariate method) did not significantly alter the results. Data from $T_4$ were not used to avoid potential confounding effects between timing of follow-up colonoscopy and completing the FFQ at $T_4$. Inclusion of the $T_4$ data did not substantially change the estimates (results not shown). To test differences between participants with different posttrial adenoma occurrence outcomes (no versus any recurrence, no versus advanced recurrence), the Wilcoxon rank-sum test was used for intakes of flavonoids and flavonoid-rich foods, the $t$ tests for other continuous variables, and the $\chi^2$ tests for categorical variables. The associations among flavonoid subgroups, flavonoid-rich foods, and other cohort characteristics were estimated using Spearman rank correlation coefficient and by using a linear trend test in which cohort characteristics are compared across age-adjusted flavonoid intake quartiles.

To estimate the strength of association between consumption of flavonoids and flavonoid-rich foods and adenoma recurrence (no versus any recurrence and no versus advanced recurrence), logistic regression models were used to compute odds ratios (OR) and 95% confidence intervals (95% CI) using the lowest intake quartile among all participants as the reference category. For evaluating linear trends across intake levels, the median values of each quartile were calculated and combined into a continuous score variable. We evaluated several potential confounders, including age; body mass index; sex; education; regular nonsteroidal anti-inflammatory drug (NSAID); family history of CRC; regular aspirin use; regular multivitamin supplement use; regular vitamin A supplement use; regular vitamin E supplement use; and intakes of folate, fiber, red meat, and saturated fat. The potential confounders were added to the models in a stepwise fashion; if it was associated with both adenoma recurrence and consumption of flavonoids and flavonoid-rich foods, had a $\chi^2$ $P$ value $\leq 0.20$, and changed the OR by more than 10%, it remained in the model. The final models included baseline ($T_0$) age (in years), body mass index (kg/m²), sex (% male), regular NSAID use (defined as at least once per month; % yes), and dietary fiber intake (g/1,000 kcal). Effect modification was evaluated by stratified analyses by sex, regular NSAID use, regular aspirin use, regular multivitamin supplement use, regular vitamin A supplement use, and regular vitamin E supplement use. All $P$ values correspond to two-sided tests. Differences were considered to be significant at $P \leq 0.05$ or after adjusting for multiple comparisons using the Bonferroni correction at $P \leq 0.083$.

## Results

At baseline, participants of the PPT were on average 61.1 years old, overweight (27.6 kg/m²), highly educated (75% with more than high school education), Caucasian (90%), and males (64%; Table 1). A high proportion of participants had a history of CRC in first-degree relatives (27%) and used NSAIDs (34%) or aspirin (23%) regularly. Furthermore, many participants regularly took supplements of multivitamins (34%), vitamin A (33%), or vitamin E (41%).

Participants with advanced recurrent adenomas were more likely to be male, older, and less likely to use NSAIDs at baseline, and participants with any recurrent adenoma were more likely to be male and older than participants with no adenoma recurrence.

A variety of fruits and vegetables contributed to the consumption of total flavonoids and its subgroups (Table 2). Total flavonoid intake was correlated positively with dietary fiber, fruit, and vegetable intakes ($r = 0.42$, 0.49, and 0.38, respectively), and with flavonoid subgroups (between $r = 0.32$ for isoflavonoids and $r = 0.80$ for flavan-3-ols).

Before the trial ($T_0$), no significant differences in intakes of total flavonoids, flavonoid subgroups, and flavonoid-rich foods were observed among participants with different adenoma recurrence outcomes (data not shown).

During the trial [average ($T_1$, $T_2$, $T_3$)], participants randomized to the intervention group increased their flavonoid consumption more than the dietary control group [median, 30.0 mg/1,000 kcal; interquartile range (IQR), 11.5–49.4 mg/1,000 kcal versus median, 5.5 mg/1,000 kcal; IQR, −9.3 to 21.8 mg/1,000 kcal; $P < 0.0001$]. Significant differences in consumption of flavanones (lower; $P = 0.005$), flavonols (higher; $P = 0.002$), and isoflavonoids (higher; $P = 0.007$), but not total flavonoids ($P = 0.74$), were observed among participants with no adenoma recurrence versus advanced adenoma recurrence (Table 3). We observed a statistically significant increased risk of advanced adenoma recurrence for the highest intake quartile of flavanones compared with the lowest (OR, 2.32; 95% CI, 1.28–4.20), which was not significant after adjusting for multiple comparisons or main dietary sources of flavanones (data not shown).

We observed a statistically significant decreased risk for the highest intake quartile of flavonols compared with the lowest (OR, 0.24; 95% CI, 0.11–0.53) and, to a smaller extent, for the highest intake quartile of isoflavonoids (OR, 0.46; 95% CI, 0.22–0.95; Table 4). The protective effect of higher isoflavonoid intake attenuated after adjusting for multiple comparisons and when the model was adjusted for intakes of dry beans and flavonols, whereas this was not the case for increased flavonol intake even after adjusting for isoflavonoid intake (data not shown). Of the individual flavonols and isoflavonoids examined, we observed a statistically significant decreased risk for advanced adenoma recurrence for greater intakes of genistein, isorhamnetin, kaempferol, and formononetin (Table 5). Greater intakes of apigenin (4th versus 1st quartile; OR, 0.60; 95% CI, 0.32–1.14; $P_{trend} = 0.04$) and (−)-epigallocatechin 3-gallate (4th versus 1st quartile; OR, 0.55; 95% CI, 0.32–0.96; $P_{trend} = 0.05$) were additionally inversely associated with advanced adenoma recurrence.

The protective effects of flavonol and isoflavonoid intake were observed only at higher intake levels. At baseline, intakes of flavonols (4th quartile daily intake >11.53 mg/1,000 kcal) and isoflavonoid s (4th quartile daily intake >0.077 mg/1,000 kcal) were lower than during the trial (flavonols, 4th quartile daily intake >17.30 mg/1,000 kcal; isoflavonoids: 4th quartile daily intake >0.133 mg/1,000 kcal), and no significant associations between intake of flavonols (4th versus 1st quartile; OR, 0.69; 95% CI, 0.38–1.24; $P_{trend} = 0.14$) and isoflavonoids (4th versus 1st quartile; OR, 0.74; 95% CI, 0.41–1.35; $P_{trend} = 0.29$) and advanced adenoma recurrence were observed. During the trial, the intervention group had higher daily flavonol (median, 16.2 mg/1,000 kcal; IQR, 11.7 to 22.0 mg/1,000 kcal versus median, 9.1 mg/1,000 kcal; IQR, 6.6 to 12.2 mg/1,000 kcal) and isoflavonoid (median, 0.209 mg/1,000 kcal; IQR, 0.133 to 0.311 mg/1,000 kcal versus median, 0.097 mg/1,000 kcal; IQR, 0.061 to 0.153 mg/1,000 kcal) consumption than the control group. After stratification by experimental group, the protective associations between advanced adenoma recurrence and intakes of flavonols (4th versus 1st quartile; OR, 0.10; 95% CI, 0.03–0.29; $P_{trend} < 0.0001$) and isoflavonoids (4th versus 1st quartile; OR, 0.29; 95% CI, 0.11–0.79; $P_{trend} = 0.002$) during the PPT were strong for the

intervention group, whereas no meaningful risk estimates could be calculated for the control group because only a small number of control group participants had high flavonol intakes.

With regard to any adenoma recurrence during the trial [average $(T_1, T_2, T_3)$], participants with any adenoma recurrence had higher intake levels of flavanones than participants with no adenoma recurrence ($P = 0.002$; Table 3), which was reflected in an increased risk of any adenoma recurrence of participants in the highest quartile of flavanone intake (OR, 1.48; 95% CI, 1.11–1.96). The observed associations were not significant after adjusting for multiple comparisons or main dietary sources of flavanones (data not shown).

## Discussion

This study is among the first to examine the association between flavonoid intake and colorectal adenoma recurrence. Total flavonoid intake was not associated with colorectal adenoma recurrence; however, we detected a reduced risk of advanced adenoma recurrence with greater flavonol consumption during the trial. Participants in the highest flavonol (in particular, isorhamnetin and kaempferol) intake quartile had a 76% decreased risk of recurrence of advanced colorectal adenomas compared with the lowest intake group. The protective effect was even stronger in the intervention group (90% decreased risk). Our results also suggest that a 4-year intervention with a flavonol-rich diet might be effective in reducing the risk of advanced colorectal adenomas.

Consistent with our results, an Italian hospital–based case-control study and a Scottish population–based case-control study reported significant 36% and 27% reduced risks of CRC, respectively, for those in the highest quartile of flavonol intake (25,26). Both studies used new, large, rigorously tested flavonoid databases (22–24) and examined multiple flavonoids; however, limitations were potential dietary recall bias and limited external validity, particularly for the hospital-based case-control study. The prospective design of our study reduces these limitations.

No association between flavonol intake and CRC cancer risk was observed in the Dutch Cohort Study on Diet and Cancer (12), the Finnish Alpha-Tocopherol Beta-Carotene Study (13), the Finnish Mobile Clinic Health Examination Survey (14,15), and the U.S. Nurses' Health Study and Health Professional Follow-up Study (16). However, these five prospective cohort studies used older and smaller flavonoid databases (17–21) and evaluated the effect of flavonols over an intake range similar or narrower than that of our participants at baseline (median, 14.9 mg/d; IQR, 10.1–21.2 mg/d), for which we also did not observe a protective association. In comparison, the median flavonol intake of our intervention group during the PPT was 29.5 mg/d (IQR, 20.7–39.8 mg/d). In support of our findings, other studies have reported a minimum of five servings of vegetables per day must be consumed before a reduction in rectal cancer risk can be observed (35) and a minimum of five servings of fruits per day before a reduction in colorectal adenomas is observed (36). Therefore, our results suggest that the protective association between flavonols and CRC might be achieved only at flavonol intake levels that are higher than what is commonly consumed by Western populations (1,2).

A protective effect of flavonols against colorectal carcinogenesis has also been reported in experimental CRC animal model studies (37–42). It has been well documented that there are a number of underlying molecular mechanisms by which flavonols inhibit CRC *in vitro*. These mechanisms include inhibition of cancer initiation by its antioxidative (43,44) and antimutagenic properties (45) and inhibiting the promotion phase of cancer by its anti-inflammatory (44,46), antiproliferative (47,48), and anti–cell transformation properties (49, 50). In addition, flavonols could also delay cancer progression by inducing apoptosis (41,47) and inhibiting matrix metalloproteinases (51) and angiogenesis (52). The cancer-protective

properties of individual flavonoids are associated with the number of hydroxyl groups on their B-ring. Consistent with our risk estimates, flavonols with a low number of hydroxyl groups (kaempferol, quercetin) exert cancer protective properties at lower concentrations than myricetin (53–55), which has the most hydroxyl groups on its B-ring.

The results for the associations between intakes of isoflavonoids and adenoma recurrence are encouraging. A protective relationship for isoflavonoid intake (24%) against CRC has been reported previously (25), whereas another study reported no association between phytoestrogens intake, which is the sum of isoflavonoids and the nonflavonoid lignans and coumestrol, and CRC risk (26). No association between flavanone consumption and CRC was reportedin either study (25,26). The associations with isoflavonoid and flavanone intakes in our study were attenuated after adjusting for their major dietary sources, which might be overadjustment, and were not statistically significant after adjusting $P$ values for multiple comparisons. Further studies will help to evaluate whether these associations are true or occurred by chance.

Rossi et al. (25) reported a protective effect of flavone (22%) and anthocyanidin intake (23%) and no effect of flavan-3-ol intake against CRC. Theodoratou et al. (26) did not observe an association between flavone or flavan-3-ol intake and CRC, and did not estimate anthocyanidin intake. The lack of an association between flavone intake and adenoma recurrence in this study has to be interpreted with caution given that the FFQ did not specifically ask for foods high in flavones, which are mostly used as garnishes. A similar limitation has to be considered for anthocyanidins because the PPT FFQ did not specifically ask for foods high in anthocyanidins. It cannot be excluded that the lack of an association between adenoma recurrence and intakes of anthocyanidins and flavan-3-ols could be partly due to the fact that our intake ranges did not cover dosages that would be protective. Specifically, anthocyanidins are prone to intestinal degradation (56) and have been shown in animal studies to be protective at concentrations much higher than examined in this study (9,57).

There are several limitations to our study. Random as well as systematic measurement error related to both the dietary assessment techniques and the nutrient database is likely present and could bias risk estimates. Participants in the intervention arm of the study were aware what dietary patterns were expected from them and might have answered the FFQ during follow-up according to the expectations of the nutritionists. However, all three types of associations (protective, null, and detrimental) for different flavonoid subgroups would be unlikely in the case of systematic measurement error.

It has to be taken into account that this is a secondary analysis and that participants were not assigned randomly to a high- or low-flavonoid diet. Significant associations between flavonoid subgroups and adenoma recurrence could have arisen by chance due to multiple comparisons. However, the gradual decreasing ORs across most of the higher flavonol intake quartiles, the strength of the association, and the consistency of the protective association across most individual flavonols are less likely due to chance.

Flavonol intake is invariably linked to a healthful diet (i.e., low saturated fat and red meat intake and high dietary fiber and folate intake) because flavonols are found in fruits and vegetables, most of which are high in phytosterols, fiber, and vitamins and low in total and saturated fatty acids. Despite adjusting for fiber intake, residual and unmeasured confounding cannot be completely excluded, although adjusting for other potential dietary CRC confounders (e.g., folate, red meat, saturated fat, and vitamin supplements) did not substantially alter the risk estimates. Furthermore, high flavonol content is a common link between all frequently consumed vegetables (dry beans, green beans and peas, and green salad) that had been reported

previously in the PPT to be protective (58). Adjusting individually for those vegetables did not attenuate the risk estimates.

Our study findings may not be generalizable to the general population because most of the participants were highly educated nonsmokers that engaged in a health-promoting life style (28,30). The protective intake levels of flavonols are far greater than what is commonly consumed in the United States and other Western countries (1,2). On the other hand, the PPT provided an excellent opportunity to examine in humans how high intake levels of flavonoids affect adenoma recurrence risk estimates. In addition, the short duration of the PPT (4 years) might require higher dietary intake levels of flavonoids than commonly consumed in the United States to see a statistically significant effect. Furthermore, dosages used in animal and cell culture studies refer to intake levels of flavonoids much higher than that consumed in the Western population.

In conclusion, our results suggest that intake of a flavonol-rich diet may reduce the risk of advanced colorectal adenoma recurrence. Our results should be considered with caution given the relatively small number of cases with advanced adenoma recurrence, the lack of a protective effect in the underlying randomized clinical trial, the relative health consciousness of the participants, and the fact that this is one of the first studies that examined the association between flavonoid intake and adenoma recurrence. Verification of these results in studies examining the association between flavonol intake and adenoma occurrence and CRC in other prospective cohorts with high-quality dietary measures and high flavonol intakes are needed to clarify the potential role of high dietary flavonol intakes in preventing CRC.

## Acknowledgments

## Appendix 1

## The Polyp Prevention Study Group

The members of the Polyp Prevention Study Group participated in the conduct of the Polyp Prevention Trial. However, the data presented in the manuscript and the conclusions drawn from them are solely the responsibility of the above listed co-authors.

National Cancer Institute—A. Schatzkin, E. Lanza, A.J. Cross, D. Corle, L.S. Freedman, C. Clifford, J. Tangrea. Bowman Gray School of Medicine—M.R. Cooper, E. Paskett (currently Ohio State University), S. Quandt, C. DeGraffinreid, K. Bradham, L. Kent, M. Self, D. Boyles, D. West, L. Martin, N. Taylor, E. Dickenson, P. Kuhn, J. Harmon, I. Richardson, H. Lee, E. Marceau. University of New York at Buffalo—M.P. Lance (currently University of Arizona), J.R. Marshall (currently Roswell Park Cancer Center), D. Hayes, J. Phillips, N. Petrelli, S. Shelton, E. Randall, A. Blake, L. Wodarski, M. Deinzer, R. Melton. Edwards Hines, Jr., Hospital, Veterans Administration Medical Center—F.L. Iber, P. Murphy, E.C. Bote, L. Brandt-Whittington, N. Haroon, N. Kazi, M.A. Moore, S.B. Orloff, W.J. Ottosen, M. Patel, R.L. Rothschild, M. Ryan, J.M. Sullivan, A. Verma. Kaiser Foundation Research Institute—B. Caan, J.V. Selby, G. Friedman, M. Lawson, G. Taff, D. Snow, M. Belfay, M. Schoenberger, K. Sampel, T. Giboney, M. Randel. Memorial Sloan-Kettering Cancer Center—M. Shike, S. Winawer, A. Bloch, J. Mayer, R. Morse, L. Latkany, D. D'Amato, A. Schaffer, L. Cohen. University of Pittsburgh—J. Weissfeld, R. Schoen, R.R. Schade, L. Kuller, B. Gahagan, A. Caggiula, C. Lucas, T. Coyne, S. Pappert, R. Robinson, V. Landis, S. Misko, L. Search. University of Utah—R.W. Burt, M. Slattery, N. Viscofsky, J. Benson, J. Neilson, R. McDivitt,

M. Briley, K. Heinrich, W. Samowitz. Walter Reed Army Medical Center—J.W. Kikendall, D.J. Mateski, R. Wong, E. Stoute, V. Jones-Miskovsky, A. Greaser, S. Hancock, S. Chandler. Data and Nutrition Coordinating Center (Westat)—J. Cahill, M. Hasson, C. Daston, B. Brewer, T. Zimmerman, C. Sharbaugh, B. O'Brien, L. Cranston, N. Odaka, K. Umbel, J. Pinsky, H. Price, A. Slonim. Central Pathologists—K. Lewin (University of California, Los Angeles), H. Appelman (University of Michigan); Laboratories—P.S. Bachorik, K. Lovejoy (Johns Hopkins University), A. Sowell (Centers for Disease Control). Data and Safety Monitoring Committee—E.R. Greenberg (chair; Dartmouth University), E. Feldman (Augusta, Georgia), C. Garza (Cornell University), R. Summers (University of Iowa), S. Weiand (through June 1995; University of Minnesota), D. DeMets (beginning July 1995; University of Wisconsin).

## References

1. Chun OK, Chung SJ, Song WO. Estimated dietary flavonoid intake and major food sources of U.S. adults. J Nutr 2007;137:1244–1252. [PubMed: 17449588]

2. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food 2005;8:281–290. [PubMed: 16176136]

3. Hou DX, Fujii M, Terahara N, Yoshimoto M. Molecular mechanisms behind the chemopreventive effects of anthocyanidins. J Biomed Biotechnol 2004;5:321–325. [PubMed: 15577196]

4. Kanadaswami C, Lee LT, Lee PP, et al. The antitumor activities of flavonoids. In Vivo 2005;19:895–909. [PubMed: 16097445]

5. Nichenametla SN, Taruscio TG, Barney DL, Exon JH. A review of the effects and mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 2006;46:161–183. [PubMed: 16431408]

6. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 2003;23:519–534. [PubMed: 12710022]

7. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002;22:19–34. [PubMed: 12055336]

8. Au A, Li B, Wang W, Roy H, Koehler K, Birt D. Effect of dietary apigenin on colonic ornithine decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different experimental models. Nutr Cancer 2006;54:243–251. [PubMed: 16898869]

9. Cooke D, Schwarz M, Boocock D, et al. Effect of cyanidin-3-glucoside and an anthoycyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis: relationship with tissue anthocyanin level. Int J Cancer 2006;119:2213–2220. [PubMed: 16823841]

10. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:401–404. [PubMed: 12750233]

11. Arts ICW, Jacobs DR Jr, Gross M, Harnack LJ, Folson AR. Dietary catechins and cancer incidence among postmenopausal women: the Iowa Women's Health Study (United States). Cancer Causes Control 2002;13:373–382. [PubMed: 12074507]

12. Goldbohm, RA.; Hertog, MGL.; Brants, HAM.; van Poppel, G.; van der Brandt, PA. Intake of flavonoids and cancer risk: a prospective cohort study. In: Armado, R.; Anderson, H.; Bardócz, S., et al., editors. Polyphenols in foods. Luxemburg: Office for Official Publications of the European Community; 1998. p. 159-166.

13. Hirvonen T, Virtamo J, Korhonen P, Albanes D, Pietinen P. Flavonol and flavone intake and the risk of cancer in male smokers (Finland). Cancer Causes Control 2001;12:789–796. [PubMed: 11714106]

14. Knekt P, Järvinen R, Seppänen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997;146:223–230. [PubMed: 9247006]

15. Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560–568. [PubMed: 12198000]

16. Lin J, Zhang SM, Wu K, Willett WC, Fuchs CS, Giovannucci E. Flavonoid intake and colorectal cancer risk in men and women. Am J Epidemiol 2006;164:644–651. [PubMed: 16923774]

17. Häkkinen SH, Kärenlampi SO, Heinonen IM, Mykkänen HM, Törrönen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 1999;47:2274–2279. [PubMed: 10794622]

18. Hertog MGL, Hollman PCH, Katan MB. Content of potentially anticarcinogenic flavonoids of 28 vegetables and fruits. J Agric Food Chem 1992;40:2379–2383.

19. Hertog MGL, Hollman PCH, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993;20:21–29. [PubMed: 8415127]

20. Hertog MGL, Hollman PCH, van de Putte B. Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juices. J Agric Food Chem 1993;41:1242–1246.

21. Sampson L, Rimm E, Hollman P, de Vries J, Katan M. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 2002;102:1414–1420. [PubMed: 12396158]

22. Kyle, JAM.; Duthie, GG. Flavonoids in foods. In: Andersen, ØM.; Markham, KR., editors. Flavonoids: chemistry, biochemistry and applications. Boca Raton: CRC/Taylor & Francis; 2006. p. 219-262.

23. U.S. Department of Agriculture, Agricultural Research Service. USDA-Iowa State University Database on the isoflavone content of foods, Release 1.3-2002; USDA. 2002. Nutrient Data Laboratory web site: http://www.ars.usda.gov/nutrientdata

24. U.S. Department of Agriculture, Agricultural Research Service. USDA Database for the flavonoid content of selected foods, Release 1-2003; USDA. 2003. Nutrient Data Laboratory homepage: http://www.ars.usda.gov/nutrientdata

25. Rossi M, Negri E, Talamini R, et al. Flavonoids and colorectal cancer in Italy. Cancer Epidemiol Biomarkers Prev 2006;15:1555–1558. [PubMed: 16896049]

26. Theodoratou E, Kyle J, Cetnarskyj, et al. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007;16:684–693. [PubMed: 17416758]

27. Bhagwat, SA.; Gebhardt, SE.; Haytowitz, DB.; Holden, JM.; Harnly, J. USDA database for the flavonoid content of selected foods, Release 2; USDA. 2006. Nutrient Data Laboratory homepage: http://www.ars.usda.gov/nutrientdata

28. Lanza E, Schatzkin A, Ballard-Barbash R, et al. The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics. Cancer Epidemiol Biomarkers Prev 1996;5:385–392. [PubMed: 9162305]

29. Schatzkin A, Lanza E, Freedman LS, et al. The Polyp Prevention Trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev 1996;5:375–383. [PubMed: 9162304]

30. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas: polyp prevention trial study group. N Engl J Med 2000;342:1149–1155. [PubMed: 10770979]

31. Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990;43:1327–1335. [PubMed: 2254769]

32. Lanza E, Schatzkin A, Daston C, et al. Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. Am J Clin Nutr 2001;74:387–401. [PubMed: 11522565]

33. Wanke KL, Daston C, Slonim A, et al. Adherence to the Polyp Prevention Trial dietary intervention is associated with a behavioral pattern of adherence to nondietary trial requirement and general health recommendations. J Nutr 2007;137:391–398. [PubMed: 17237317]

34. Hudson TS, Forman MR, Cantwell MM, et al. Dietary fiber intake: assessing the degree of agreement between food frequency questionnaires and 4-day food records. J Am Coll Nutr 2006;25:370–381. [PubMed: 17031005]

35. Slattery ML, Curtin KP, Edwards SL, Schaffer DM. Plant foods, fiber and rectal cancer. Am J Clin Nutr 2004;79:274–281. [PubMed: 14749234]

36. Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC. Fruit and vegetable consumption and colorectal adenomas in the Nurses' Health Study. Cancer Res 2006;66:3942–3953. [PubMed: 16585224]

37. Deschner EE, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethane-induced colonic neoplasia. Carcinogenesis 1991;12:1193–1196. [PubMed: 2070483]

38. Deschner EE, Ruperto JF, Wong GY, Newmark HL. The effect of dietary quercetin and rutin on AOM-induced acute colonic epithelial abnormalities in mice fed a high-fat diet. Nutr Cancer 1993;20:199–204. [PubMed: 8108270]

39. Matsukawa Y, Nishino H, Okuyama Y, et al. Effects of quercetin and/or restraint stress on formation of aberrant crypt foci induced by azoxymethane in rat colons. Oncology 1997;54:118–121. [PubMed: 9075782]

40. Volate SR, Davenport DM, Muga SJ, Wargovich MJ. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng, and rutin). Carcinogenesis 2005;26:1450–1456. [PubMed: 15831530]

41. Wargovich MJ, Jimenez A, McKee K, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000;21:1149–1155. [PubMed: 10837003]

42. Yang K, Lamprecht SA, Liu Y, et al. Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 2000;21:1655–1660. [PubMed: 10964096]

43. Duthie SJ, Dobson VL. Dietary flavonoids protect human colonocyte DNA from oxidative attack *in vitro*. Eur J Nutr 1999;38:28–34. [PubMed: 10338685]

44. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ. Distinctive antioxidant and anti-inflammatory effects of flavonols. J Agric Food Chem 2006;54:9798–9804. [PubMed: 17177504]

45. Ruf AA, Webb J, Anderson D. Modulation by flavonoids of the effect of a food mutagen in different thalassaemia genotypes in the Comet Assay. Teratog Carcinog Mutagen 2003:93–102. [PubMed: 14691983]

46. García-Mediavilla V, Crespo I, Collado PS, et al. The anti-inflammatory cytokines quercetin and kaempferol cause inhibition of nitric oxide synthase, cyclooxygenase 2 and reactive protein C, and down-regulation of the nuclear factor κB pathway in Chang liver cells. Eur J Pharmacol 2007;557:221–229. [PubMed: 17184768]

47. Kim WK, Bang MH, Kim ES, et al. Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells. J Nutr Biochem 2005;16:155–162. [PubMed: 15741050]

48. Richter M, Ebermann R, Marian B. Quercetin-induced apoptosis in colorectal tumor cells: possible role of EGF receptor signaling. Nutr Cancer 1999;34:88–99. [PubMed: 10453447]

49. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong ANT. Modulation of activator protein-1 (AP-1) and MAPK pathway for flavonoids in human prostate cancer PC3 cells. Arch Pharm Res 2006;29:633–644. [PubMed: 16964758]

50. Ichimatsu D, Nomura M, Nakamura S, et al. Structure activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells. Mol Carcinog 2007;46:436–445. [PubMed: 17219438]

51. Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataran P, Krishnamoorthy G, Arunakaran J. Quercetin down-regulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 2006;287:109–116. [PubMed: 16645725]

52. Kim JD, Liu L, Guo W, Meydani M. Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion. J Nutr Biochem 2006;17:165–176. [PubMed: 16169200]

53. Agullo G, Gamet-Parastre L, Fernandez Y, Anciaux N, Demigné C, Rémésy C. Comparative effects of flavonoids on the growth, viability, and metabolism of a colonic adenocarcinoma cell line (HT29 cells). Cancer Lett 1996;105:61–70. [PubMed: 8689634]

54. Brusselmans K, Vrolix R, Verhoeven G, Swinnen J. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280:5636–5645. [PubMed: 15533929]

55. Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ. Flavonoids inhibit tumor necrosis factor-α-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-κB: structure-activity relationships. Mol Pharmacol 2004;66:683–693. [PubMed: 15322261]

56. Seeram NP, Bourquin LD, Nair MG. Degradation products of cyanidin glycosides from tart cherries and their bioactivities. J Agric Food Chem 2001;49:4924–4929. [PubMed: 11600045]

57. Bobe G, Wang B, Seeram NP, Nair MG, Bourquin LD. Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC[Min] mice fed suboptimal levels of sulindac. J Agric Food Chem 2006;54:9322–9328. [PubMed: 17147414]

58. Lanza E, Hartman TJ, Albert PS, et al. High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the Polyp Prevention Trial. J Nutr 2006;136:1896–1903. [PubMed: 16772456]

**Table 1**

Baseline characteristics of participants in the PPT-based cohort by adenoma recurrence

| Characteristic | Overall | No recurrence | Advanced recurrence[*] | | Any recurrence[†] | |
|---|---|---|---|---|---|---|
| | Mean (SD) | Mean (SD) | Mean (SD) | P | Mean (SD) | P |
| Sample size | 1,905 | 1,151 | 125 | 125/1,151 | 754 | 754/1,151 |
| Age, y | 61.1 (9.9) | 59.9 (10.1) | 65.2 (9.2) | <0.0001 | 62.8 (9.2) | <0.0001 |
| Body mass index (kg/m$^2$) | 27.6 (3.9) | 27.4 (4.0) | 28.0 (4.1) | 0.10 | 27.8 (3.9) | 0.05 |
| Gender (% male) | 64 | 60 | 70 | 0.02 | 72 | <0.0001 |
| Race (% Caucasian) | 90 | 90 | 90 | 0.99 | 90 | 0.97 |
| Education (% ≤high school) | 25 | 24 | 28 | 0.35 | 26 | 0.49 |
| NSAID use (% yes) | 34 | 35 | 24 | 0.01 | 31 | 0.11 |
| Aspirin use (% yes) | 23 | 23 | 19 | 0.28 | 22 | 0.55 |
| Multivitamin use (% yes) | 34 | 35 | 31 | 0.34 | 32 | 0.18 |
| Vitamin A use (% yes) | 33 | 35 | 30 | 0.24 | 31 | 0.10 |
| Vitamin E use (% yes) | 41 | 42 | 38 | 0.43 | 40 | 0.45 |
| Energy intake (MJ/d) | 8.05 (2.44) | 7.97 (2.36) | 7.93 (2.65) | 0.86 | 8.16 (2.55) | 0.11 |
| Fruit intake (g/d) | 156 (122) | 152 (115) | 166 (126) | 0.19 | 162 (127) | 0.07 |
| Vegetable intake (g/d) | 270 (132) | 268 (125) | 256 (108) | 0.25 | 273 (120) | 0.43 |
| Family history of CRC (% yes) | 27 | 27 | 26 | 0.96 | 27 | 0.77 |

NOTE: Results are presented as means (SD) for continuous variables and % for categorical variables with P values for differences in means determined by t tests and differences in proportions determined by $\chi^2$ tests. Adenomatous polyp recurrence and advanced adenoma recurrence were diagnosed using full colonoscopy at the end of year 4.

[*] Comparison between the advanced adenoma recurrence group to the no adenoma recurrence group.

[†] Comparison between the any adenoma recurrence group to the no adenoma recurrence group.

**Table 2**

Main dietary sources of total flavonoids and flavonoid subgroups among participants during the PPT ($n$ = 1,859)

| Flavonoid | Main dietary sources (≥5% of total intake)[*] |
|---|---|
| Total flavonoids | Tea (30.0%), citrus fruit juices (17.2%), other fruits (grapes, plums, pineapples: 8.9%), oranges (7.2%), dry beans (6.0%), grapefruits (5.6%) |
| Anthocyanins | Other fruits (grapes, plums, pineapples: 44.8%), bananas (18.7%), other fruit juices (apple, cranberry, and grape juices: 13.5%), fresh strawberries (7.0%), apples (5.4%) |
| Flavan-3-ols | Tea (70.5%), other fruits (grapes, plums, pineapples: 6.2%), apples (6.2%), bananas (5.1%) |
| Flavanones | Citrus fruit juices (57.1%), oranges (23.4%), grapefruit (18.5%) |
| Flavones | Other vegetables (onions, cucumbers, celery, radishes, peppers: 39.5%), oranges (19.1%), iceberg/red leaf lettuce (7.4%), watermelons (7.3%), wine (7.0%) |
| Flavonols | Dry beans (32.2%), other vegetables (onions, cucumbers, celery, radishes, peppers: 17.8%), tea (9.6%), apples (5.4%) |
| Isoflavonoids | Dry beans (47.1%), peas (43.6%), chili (5.1%) |

[*] Flavonoid contents of foods based on USDA flavonoid database release 2 (27); isoflavonoid contents of foods based on USDA isoflavonoid database release 1.3 (23). Contributions of individual foods to composite foods (e.g., other fruits, other fruit juices, other vegetables) are described in Table 3.

**Table 3**

Energy-adjusted medians and IQRs of daily intakes of total flavonoids, flavonoid subgroups, and flavonoid-rich foods among participants during the PPT by adenoma recurrence

| Dietary component* | Overall Median (IQR) | No recurrence Median (IQR) | Advanced recurrence† Median (IQR) | P | Any recurrence‡ Median (IQR) | P |
|---|---|---|---|---|---|---|
| | 1,859 | 1,123 | 123 | 123/1123 | 736 | 736/1,123 |
| Flavonoids (in mg/1,000 kcal) | | | | | | |
| Total flavonoids | 76.2 (50.9–106.1) | 76.1 (50.1–105.3) | 72.2 (51.1–104.6) | 0.74 | 76.3 (52.2–106.4) | 0.53 |
| Anthocyanins | 10.1 (5.70–15.6) | 10.2 (5.61–16.0) | 9.85 (5.68–13.91) | 0.52 | 9.83 (5.82–15.3) | 0.30 |
| Flavan-3-ols | 17.3 (10.2–38.6) | 17.8 (10.4–39.4) | 15.7 (9.20–29.9) | 0.13 | 16.7 (9.92–37.6) | 0.36 |
| Flavanones | 22.7 (10.6–36.9) | 21.6 (9.88–35.3) | 24.5 (14.4–44.8) | 0.005 | 24.2 (12.5–39.5) | 0.002 |
| Flavones | 0.73 (0.46–1.10) | 0.73 (0.46–1.09) | 0.72 (0.43–1.11) | 0.56 | 0.73 (0.45–1.11) | 0.59 |
| Flavonols | 12.0 (9.12–17.3) | 12.3 (8.19–17.6) | 10.3 (7.55–14.1) | 0.002 | 11.5 (8.04–17.1) | 0.30 |
| Isoflavonoids | 0.08 (0.04–0.13) | 0.08 (0.04–0.14) | 0.07 (0.04–0.10) | 0.007 | 0.07 (0.05–0.13) | 0.46 |
| Flavonoid-rich foods (in g/1,000 kcal) | | | | | | |
| Bananas | 23.5 (10.5–43.1) | 23.5 (10.7–42.6) | 23.6 (12.0–45.2) | 0.57 | 23.4 (10.2–43.6) | 0.91 |
| Grapefruits | 4.36 (0–15.9) | 3.84 (0–14.6) | 6.22 (1.23–18.3) | 0.02 | 5.20 (0.77–18.0) | 0.004 |
| Oranges | 10.5 (3.55–23.96) | 10.2 (3.41–22.8) | 11.9 (4.19–28.6) | 0.51 | 11.3 (4.10–25.9) | 0.21 |
| Citrus fruit juices | 34.1 (8.04–78.1) | 32.9 (7.32–76.8) | 40.9 (9.98–84.6) | 0.10 | 36.7 (8.78–81.9) | 0.04 |
| Other fruits§ | 12.3 (3.72–28.3) | 12.7 (3.74–30.0) | 9.70 (3.60–25.2) | 0.25 | 11.1 (3.66–26.9) | 0.25 |
| Other fruit juices‖ | 9.31 (1.30–32.4) | 9.92 (1.41–33.0) | 10.1 (1.05–30.7) | 0.80 | 11.1 (3.66–26.9) | 0.12 |
| Dry beans | 8.58 (3.63–19.4) | 8.85 (3.67–20.0) | 6.17 (3.41–13.43) | 0.006 | 8.02 (3.52–19.0) | 0.30 |
| Peas | 4.86 (2.44–8.76) | 4.88 (2.37–8.74) | 4.75 (2.19–7.91) | 0.46 | 4.81 (2.47–8.82) | 0.80 |
| Other vegetables¶ | 25.4 (12.3–45.7) | 25.9 (11.8–46.6) | 20.8 (9.76–35.6) | 0.009 | 25.0 (13.2–44.4) | 0.99 |
| Tea | 7.05 (0–49.8) | 7.60 (0–52.5) | 3.00 (0–38.4) | 0.07 | 6.30 (0–47.6) | 0.48 |

NOTE: Daily intakes of flavonoids and flavonoid-rich foods (contributed ≥5% of total flavonoid or ≥10% of flavonoid subgroup consumption) are for the first 3 y of the PPT and were energy adjusted by dividing through total caloric intake in 1,000 kcal (4.184 MJ). Adenomatous polyp recurrence (any or advanced) was diagnosed through postintervention at year 4.

*Energy-adjusted intakes of flavonoids and flavonoid-rich foods are presented as energy-adjusted medians and interquartile ranges with P values for differences in energy-adjusted means determined by Wilcoxon rank sum test.

†Comparison between the adenoma recurrence group to the no adenoma recurrence group.

‡Comparison between the advanced adenoma recurrence group to the no adenoma recurrence group.

§Other fruits (46% grapes, 31% plums, and 23% pineapples).

‖Other fruit juices (50% apple juice, 25% cranberry juice, and 25% grape juice).

¶Other vegetables (30% white onions, 5% red onion, 27% cucumbers, 16% celery, 12% radishes, and 10% pepper).

**Table 4**

Association between total flavonoid and flavonoid subgroup consumption and colorectal adenoma recurrence among participants during the PPT (n = 1,859)

| Quartile | Range | No recurrence Controls | Advanced recurrence Cases | Advanced recurrence OR (95% CI) | Any recurrence Cases | Any recurrence OR (95% CI) |
|---|---|---|---|---|---|---|
| | | | 123 | | 736 | |
| **Total flavonoids** | | | | | | |
| 1 | <50.87* | 293 | 30 | 1.00[†] | 171 | 1.00[†] |
| 2 | 50.87–76.12 | 269 | 36 | 1.32(0.76–2.27) | 196 | 1.27(0.96–1.68) |
| 3 | 76.21–106.0 | 283 | 27 | 0.97(0.54–1.76) | 182 | 1.14(0.85–1.53) |
| 4 | >106.0 | 278 | 30 | 1.15(0.64–2.07) | 187 | 1.25(0.93–1.67) |
| $P_{trend}$ | | | | 0.94 | | 0.27 |
| **Anthocyanins** | | | | | | |
| 1 | <5.70 | 289 | 31 | 1.00 | 175 | 1.00 |
| 2 | 5.70–10.06 | 265 | 32 | 1.13(0.64–1.98) | 200 | 1.27(0.96–1.69) |
| 3 | 10.07–15.58 | 281 | 30 | 1.06(0.57–1.95) | 184 | 1.17(0.86–1.59) |
| 4 | >15.58 | 288 | 30 | 1.13(0.57–2.25) | 177 | 1.13(0.80–1.60) |
| $P_{trend}$ | | | | 0.80 | | 0.65 |
| **Flavan-3-ols** | | | | | | |
| 1 | <10.22 | 273 | 35 | 1.00 | 191 | 1.00 |
| 2 | 10.23–17.22 | 273 | 35 | 1.05 (0.62–1.80) | 192 | 1.03 (0.78–1.36) |
| 3 | 17.30–38.57 | 292 | 30 | 0.92 (0.53–1.60) | 173 | 0.89 (0.67–1.18) |
| 4 | >38.57 | 285 | 23 | 0.65 (0.37–1.15) | 180 | 0.94 (0.71–1.23) |
| $P_{trend}$ | | | | 0.12 | | 0.44 |
| **Flavanones** | | | | | | |
| 1 | <10.57 | 305 | 20 | 1.00 | 159 | 1.00 |
| 2 | 10.79–21.97 | 281 | 34 | 1.74 (0.96–3.15) | 184 | 1.21 (0.92–1.59) |
| 3 | 22.00–36.86 | 280 | 37 | 1.39 (0.75–2.57) | 185 | 1.21 (0.92–1.60) |
| 4 | >36.87 | 257 | 42 | 2.32 (1.28–4.20) | 208 | 1.48 (1.11–1.96) |
| $P_{trend}$ | | | | 0.02 | | 0.01 |
| **Flavones** | | | | | | |
| 1 | <0.46 | 277 | 36 | 1.00 | 187 | 1.00 |
| 2 | 0.46–0.73 | 285 | 29 | 0.79 (0.45–1.37) | 180 | 0.97 (0.73–1.28) |
| 3 | >0.73–1.10 | 286 | 27 | 0.84 (0.46–1.55) | 179 | 1.05 (0.77–1.42) |
| 4 | >1.10 | 275 | 31 | 1.08 (0.55–2.10) | 190 | 1.18 (0.84–1.66) |
| $P_{trend}$ | | | | 0.82 | | 0.31 |
| **Flavonols** | | | | | | |
| 1 | <8.12 | 277 | 39 | 1.00 | 187 | 1.00 |
| 2 | 8.12–12.01 | 263 | 40 | 0.97(0.58–1.62) | 202 | 1.19(0.91–1.57) |
| 3 | 12.03–17.30 | 294 | 31 | 0.61(0.34–1.10) | 171 | 0.89(0.66–1.20) |
| 4 | >17.30 | 289 | 13 | 0.24(0.11–0.53) | 176 | 0.96(0.68–1.36) |
| $P_{trend}$ | | | | 0.0006 | | 0.47 |
| **Isoflavonoids** | | | | | | |
| 1 | <0.045 | 286 | 37 | 1.00 | 178 | 1.00 |
| 2 | 0.045–0.079 | 261 | 41 | 1.04(0.63–1.72) | 204 | 1.17(0.90–1.54) |
| 3 | >0.079–0.133 | 286 | 26 | 0.59(0.33–1.06) | 179 | 0.96(0.72–1.29) |
| 4 | >0.133 | 290 | 19 | 0.46(0.22–0.95) | 175 | 1.02(0.74–1.42) |
| $P_{trend}$ | | | | 0.01 | | 0.81 |

All models were adjusted for age, sex, body mass index, dietary fiber consumption, and regular NSAID use. Adenomatous polyp recurrence (any or advanced) was diagnosed through postintervention at year 4.

*
Average daily total flavonoid and individual flavonoid intakes (in mg) are for the first 3 y of the PPT and were energy-adjusted by dividing through total caloric intake in 1,000 kcal (4.184 MJ).

†
Reference category.

**Table 5**

Association between individual flavanone, flavonol, and isoflavonoid consumption and colorectal adenoma recurrence among participants during the PPT ($n = 1,859$)

| Quartile | Ranges | No recurrence | Advanced recurrence | | Any recurrence | |
|---|---|---|---|---|---|---|
| | | Controls | Cases | OR (95% CI) | Cases | OR (95% CI) |
| | | | 123 | | 736 | |
| **Flavanones** | | | | | | |
| Hesperetin | | | | | | |
| 1 | <6.13* | 300 | 22 | 1.00[†] | 164 | 1.00[†] |
| 2 | 6.14–13.98 | 284 | 26 | 1.15 (0.63–2.11) | 181 | 1.14 (0.86–1.49) |
| 3 | 13.99–25.35 | 262 | 38 | 1.89 (1.07–3.33) | 203 | 1.40 (1.07–1.84) |
| 4 | >25.35 | 277 | 37 | 1.66 (0.94–2.95) | 188 | 1.16 (0.88–1.53) |
| $P_{trend}$ | | | | 0.03 | | 0.14 |
| Naringenin | | | | | | |
| 1 | <2.93 | 301 | 24 | 1.00 | 163 | 1.00 |
| 2 | 2.93–5.72 | 283 | 27 | 1.18 (0.66–2.13) | 182 | 1.18 (0.90–1.55) |
| 3 | 5.73–10.47 | 282 | 38 | 1.59 (0.90–2.80) | 183 | 1.17 (0.88–1.54) |
| 4 | >10.47 | 257 | 34 | 1.52 (0.84–2.77) | 208 | 1.46 (1.09–1.95) |
| $P_{trend}$ | | | | 0.11 | | 0.02 |
| **Flavonols** | | | | | | |
| Isorhamnetin | | | | | | |
| 1 | <0.15 | 290 | 36 | 1.00 | 174 | 1.00 |
| 2 | 0.15–0.28 | 266 | 37 | 1.12 (0.68–1.87) | 199 | 1.26 (0.96–1.65) |
| 3 | >0.28–0.46 | 278 | 35 | 1.02 (0.60–1.74) | 187 | 1.16 (0.88–1.55) |
| 4 | >0.46 | 289 | 15 | 0.44 (0.21–0.90) | 176 | 1.11 (0.81–1.53) |
| $P_{trend}$ | | | | 0.07 | | 0.60 |
| Kaempferol | | | | | | |
| 1 | <2.69 | 274 | 35 | 1.00 | 190 | 1.00 |
| 2 | 2.69–4.73 | 284 | 41 | 1.07 (0.65–1.77) | 181 | 0.90 (0.68–1.17) |
| 3 | 4.75–8.63 | 274 | 30 | 0.83 (0.47–1.46) | 191 | 1.00 (0.75–1.33) |
| 4 | >8.64 | 291 | 17 | 0.44 (0.22–0.89) | 174 | 0.91 (0.66–1.25) |
| $P_{trend}$ | | | | 0.03 | | 0.73 |
| Myricetin | | | | | | |
| 1 | <0.35 | 278 | 28 | 1.00 | 186 | 1.00 |
| 2 | 0.35–0.54 | 279 | 40 | 1.57 (0.93–2.67) | 186 | 1.06 (0.81–1.38) |
| 3 | >0.54–0.89 | 278 | 28 | 1.10 (0.62–1.93) | 187 | 1.05 (0.80–1.38) |
| 4 | >0.89 | 288 | 27 | 1.01 (0.57–1.77) | 177 | 1.01 (0.77–1.32) |
| $P_{trend}$ | | | | 0.67 | | 0.98 |
| Quercetin | | | | | | |
| 1 | <4.12 | 292 | 34 | 1.00 | 172 | 1.00 |
| 2 | 4.12–5.88 | 249 | 45 | 1.55 (0.93–2.58) | 216 | 1.60 (1.21–2.12) |
| 3 | 5.89–7.92 | 291 | 25 | 0.68 (0.36–1.27) | 174 | 1.11 (0.82–1.51) |
| 4 | >7.92 | 291 | 19 | 0.59 (0.29–1.20) | 174 | 1.23 (0.88–1.73) |
| $P_{trend}$ | | | | 0.04 | | 0.71 |
| **Isoflavonoids** | | | | | | |
| Biochanin A | | | | | | |
| 1 | <0.027 | 283 | 36 | 1.00 | 181 | 1.00 |
| 2 | 0.027–0.050 | 269 | 34 | 0.90 (0.53–1.52) | 196 | 1.08 (0.82–1.42) |
| 3 | >0.050–0.084 | 276 | 34 | 0.87 (0.50–1.52) | 189 | 1.03 (0.77–1.38) |
| 4 | >0.084 | 295 | 19 | 0.50 (0.25–1.04) | 170 | 0.95 (0.69–1.33) |
| $P_{trend}$ | | | | 0.11 | | 0.75 |
| Daidzein | | | | | | |
| 1 | <0.0012 | 290 | 37 | 1.00 | 174 | 1.00 |
| 2 | 0.0012–0.0019 | 265 | 37 | 1.09 (0.66–1.81) | 200 | 1.20 (0.91–1.57) |

| Quartile | Ranges | No recurrence | Advanced recurrence | | Any recurrence | |
|---|---|---|---|---|---|---|
| | | Controls | Cases | OR (95% CI) | Cases | OR (95% CI) |
| 3 | 0.0020–0.0030 | 285 | 38 | 0.78 (0.45–1.37) | 180 | 1.05 (0.79–1.39) |
| 4 | >0.0030 | 283 | 21 | 0.62 (0.32–1.17) | 182 | 1.13 (0.83–1.53) |
| $P_{trend}$ | | | | 0.10 | | 0.64 |
| Formononetin | | | | | | |
| 1 | <0.0004 | 275 | 39 | 1.00 | 189 | 1.00 |
| 2 | 0.0004–0.0007 | 279 | 38 | 0.87 (0.53–1.42) | 186 | 0.90 (0.68–1.18) |
| 3 | 0.0007–0.0011 | 283 | 25 | 0.61 (0.34–1.10) | 182 | 0.92 (0.70–1.23) |
| 4 | >0.0011 | 286 | 21 | 0.49 (0.26–0.95) | 179 | 0.94 (0.69–1.29) |
| $P_{trend}$ | | | | 0.02 | | 0.76 |
| Genistein | | | | | | |
| 1 | <0.016 | 283 | 40 | 1.00 | 181 | 1.00 |
| 2 | 0.016–0.028 | 271 | 41 | 0.93 (0.57–1.51) | 194 | 1.04 (0.79–1.36) |
| 3 | >0.028–0.046 | 278 | 24 | 0.55 (0.31–0.99) | 187 | 1.04 (0.78–1.38) |
| 4 | >0.046 | 291 | 18 | 0.38 (0.19–0.76) | 174 | 0.98 (0.71–1.35) |
| $P_{trend}$ | | | | 0.003 | | 0.93 |

NOTE: All models were adjusted for age, sex, body mass index, dietary fiber consumption, and regular NSAID use. Adenomatous polyp recurrence (any or advanced) was diagnosed through postintervention at year 4.

*
Average daily individual flavanone, flavonol, and isoflavonoid intakes (in mg) are for the first 3 y of the PPT and were energy-adjusted by dividing through total caloric intake in 1,000 kcal (4.184 MJ).

†
Reference category.